NK Cells in Cord Blood Transplantation
Public ClinicalTrials.gov record NCT01619761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Natural Killer Cells in Allogeneic Cord Blood Transplantation
Study identification
- NCT ID
- NCT01619761
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 13 participants
Conditions and interventions
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Biphenotypic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia in Remission
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- DS Stage II Plasma Cell Myeloma
- DS Stage III Plasma Cell Myeloma
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- ISS Stage II Plasma Cell Myeloma
- ISS Stage III Plasma Cell Myeloma
- Myelodysplastic Syndrome
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Acute Lymphoblastic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Lenalidomide Drug
- Melphalan Drug
- Mycophenolate Mofetil Drug
- Natural Killer Cell Therapy Biological
- Rituximab Biological
- Tacrolimus Drug
- Total-Body Irradiation Radiation
- Umbilical Cord Blood Transplantation Procedure
Procedure · Drug · Other + 2 more
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2013
- Primary completion
- Oct 31, 2021
- Completion
- Oct 31, 2021
- Last update posted
- Feb 10, 2020
2013 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01619761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2020 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01619761 live on ClinicalTrials.gov.